First-degree relatives of cancer patients: a target group for primary prevention? A cross-sectional study

Haug, Ulrike; Riedel, Oliver; Cholmakow-Bodechtel, Constanze; Olsson, Louise

doi:10.1038/s41416-018-0057-2

Cited by 19 publications

(11 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous smoking was associated with higher risk of cardiac toxicity while active and no smoking did not, although in our sample active smoking and not-smoking patients presented a higher incidence of cardiac comorbidities. One possible explanation is that subjects with a familiar higher risk of either cancer or cardiovascular disease quitted smoking to prevent future illness [ 23 , 24 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab

et al. 2021

View full text Add to dashboard Cite

Background Few data are available about real-life cardiotoxicity associated with s.c. versus i.v. trastuzumab treatment of early-stage, HER2-positive breast cancer, and little is known about its predisposing factors. Patients and methods We retrospectively reviewed data of 363 adult patients treated with adjuvant trastuzumab for HER2-positive breast cancer. Univariate statistical analysis was performed, and a multivariable logistic model was developed to identify independent risk factors of cardiac toxicity. Results Within 5 years, the overall incidence of events meeting our criteria was 11.8%, and an early discontinuation of trastuzumab was recorded in 20 patients (5.5%). No cases of congestive heart failure occurred, neither multiple events per patient were observed. A total of 184 patients received i.v. and 179 received s.c. trastuzumab. Compared with the s.c. formulation, a higher cardiotoxicity rate for the i.v. administration (15.2% vs 8.4%) was found, and particularly in those patients with cardiovascular risk factors (19.3% vs 8.7%), at the univariate and multivariate analyses. Although more patients with prior anthracycline-based chemotherapy experienced cardiac events, the association of this therapy with cardiac events was not significant. The incidence of cardiac events was not influenced by anthropometric data (e.g. body mass index) or a diagnosis of diabetes mellitus. 5-year event-free survival was 91.7% in the overall population; event-free survival rates were similar between the s.c. and the i.v. groups. Conclusion Our study shows a more favorable safety profile of s.c. versus i.v trastuzumab administration. The use of s.c. trastuzumab could be advisable in at-risk patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab

et al. 2021

View full text Add to dashboard Cite

show abstract

“…These results are consistent with those observed in previous studies. In addition, several authors suggest that having loved ones with a history of cancer acts as a facilitator for the development of preventive attitudes [22] and behaviors [23].…”

Section: Discussionmentioning

confidence: 99%

Development and validation of the MARA scale in Spanish to assess knowledge and perceived risks and barriers relating to breast cancer prevention

Martínez-Urquijo

Postigo

Izquierdo

et al. 2021

Cancer Causes Control

View full text Add to dashboard Cite

Objective The aim of this study was to develop a measurement instrument for assessing knowledge of breast cancer and perceived risk of developing the disease (MARA). Methods 641 women with a mean age of 36.19 years (SD = 7.49) participated in the study. Data collection took place during 2019 and included sociodemographic data, data on history of cancer and breast cancer, perceived risk, and feelings of concern about developing breast cancer. Internal consistency, test–retest reliability, convergent validity, and structural validity were tested. Results The questionnaire items comprise 4 subscales: risk factors (9 items), signs and symptoms (9 items), perceived risk (6 items), barriers (7 items). A factor analysis revealed that the first two subscales had two dimensions each, whereas the other two subscales had one dimension each. Each subscale was shown to have adequate reliability (α = 0.74–0.92) and temporal stability (r = 0.201–0.906), as well as strong evidence of validity in relation to a questionnaire on breast cancer knowledge (r = 0.131–0.434). In addition, the subscales were shown to have high discriminatory power in terms of the presence or absence of a history of cancer or breast cancer, perceived risk, and feelings of concern. Conclusion The MARA questionnaire represents a valid, reliable tool for assessing Spanish women’s knowledge, risks, perceptions, and barriers regarding breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Development and validation of the MARA scale in Spanish to assess knowledge, risks and barriers relating to breast cancer prevention

Martínez-Urqujo

Postigo

Cuesta

et al. 2021

Preprint

View full text Add to dashboard Cite

Objective The aim of this study was to develop a measurement instrument for assessing knowledge of breast cancer and perceived risk of developing the disease (MARA). Methods 641 women with a mean age of 36.19 years (SD = 7.49) was used. Data collection took place during 2019 and included sociodemographic data, data on history of cancer and breast cancer and perceived risk and feelings of concern about developing breast cancer. Internal consistency, test-retest reliability, convergent validity, and structural validity were tested. Results The questionnaire items comprise 4 subscales: risk factors; signs and symptoms; perceived risk; barriers. A factor analysis revealed that the first two subscales had two dimensions each, whereas the other two subscales had one dimension each. Each subscale was shown to have adequate reliability (α = 0.74–0.92) and temporal stability (r = 0.201–0.906), as well as strong evidence of validity in relation to a questionnaire on breast cancer knowledge (r = 0.131–0.434). In addition, the subscales were shown to have high discriminatory power in terms of the presence or absence of a history of cancer or breast cancer, perceived risk, and feelings of concern. Conclusion The MARA questionnaire exhibits adequate psychometric properties for assessing knowledge of breast cancer as required in research and professional contexts.

show abstract

First-degree relatives of cancer patients: a target group for primary prevention? A cross-sectional study

Cited by 19 publications

References 25 publications

Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab

Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab

Development and validation of the MARA scale in Spanish to assess knowledge and perceived risks and barriers relating to breast cancer prevention

Development and validation of the MARA scale in Spanish to assess knowledge, risks and barriers relating to breast cancer prevention

Contact Info

Product

Resources

About